Tech Transfer Central

Myriad: The Gene Patent Fight Continues…

Format: On-Demand Video, DVD, or PDF Transcript
Originally presented: October 04, 2012

Twitter Facebook Linkedin Pinterest Email
Price: $197
order optionsorder buttonorder buttonorder button view cart

On August 16, the U.S. Federal Circuit Court of Appeals upheld Myriad’s right to patent “isolated” genes known as BRCA1 and BRCA2, which account for most inherited forms of breast and ovarian cancers. But the court denied the company’s effort to patent methods of “comparing” or “analyzing” DNA sequences. This latest development continues to raise concerns about the future of gene patenting and the development of gene-based diagnostics.

Attorney Kevin E. Noonan, PhD, of McDonnell Boehnen Hulbert & Berghoff LLP, notes that the decision leaves plenty of open questions and room for interpretation. What does it all mean for TTOs and university researchers with gene-based innovations, in terms of both patenting and licensing? In addition, the decision is likely not the last word on the matter, with a Supreme Court case likely on next year’s docket – a particular worry since the related ruling in Prometheus (and the Supremes’ directive to re-hear Myriad at the Fed Circuit) seem to hint at skepticism over lines drawn around “products of nature.”

Join Dr. Noonan for a one-hour webinar that will deeply analyze the most recent decision and discuss how the opinion affects your university and its relevant IP. He’ll discuss:

  • What the past has revealed:
    • The first CAFC decision
    • Enter Prometheus – GVR from the Supreme Court
    • The second CAFC decision
  • What the future holds:
    • En banc considerations
    • Certiorari petition
  • What university TTOs should do now:
    • Patent or wait for more clarification?
    • Patent drafting: Key factors to apply in your claims
    • Licensing: Green light or caution?
Your Expert Presenter:

Kevin E. Noonan, PhD, is a Partner with McDonnell Boehnen Hulbert & Berghoff LLP and has extensive experience in biotechnology and the chemical arts. Dr. Noonan brings more than 10 years of experience as a molecular biologist working on high-technology problems to his legal work. He has wide experience in all aspects of patent prosecution, interferences, litigation, and client counseling on validity, infringement, and patenting strategy matters. He represents pharmaceutical and biotechnology companies both large and small, and he is particularly experienced in representing university clients in both patent prosecution and licensing.

Our Guarantee of Quality and Value
We stand 100% behind the quality and value of our products. If you are dissatisfied, simply let us know and we will send you an immediate refund for your entire order -- no questions asked.

CLP and CLE Credits Available
Many state bars require written certification of attendance from the program sponsor. When you receive the access instructions for a live webinar, you will be directed to a webpage to download program materials. Included in these materials is an attendance form which should be completed and returned to us immediately following the presentation.

Please review your State Bar’s policy on distance learning credits prior to submitting the non-refundable application fee. We submit CLE applications (excluding NY, NJ, IL, LA & PA) for an additional $50 (unless otherwise specified upon checkout). Approval times vary per state and cover all attorneys in attendance. Application is not a guarantee of approval and attendance forms must be submitted following the program.

CLP Credits are also available.

order buttonorder buttonorder button
view cart

Click here for a printable order form